On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) Sees Opportunity in Applying Novel Skin Remedies to Health Concerns

  • Therma Bright’s thermal, dermatological technologies finding value in responding to array of concerns, from pain to pandemics
  • Wider cosmeceutical industry expected to grow at CAGR of 8.21 percent between 2017 and 2023
  • Therma Bright’s niche focus is in strengthening skin defenses through non-invasive infrared energy and cannabidiol properties

Skin health is a critical component of a person’s overall wellness, and the researchers at Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) are making dermatological defenses the first line of resistance against a variety of medical concerns ranging from pain to pandemics.

The medical device developer has been an innovator in the field of using infrared light to tackle skin maladies by delivering controlled topical heat to afflicted areas without a risk of burning the skin. The technology was introduced as the trademarked InterceptCS product to treat cold sores by killing cells infected with the herpes simplex Type 1 virus. Design and engineering of the system was completed in late 2005 and in April 2006 (http://cnw.fm/xGuO6).*

More recently, the company has been advancing its TherOZap technology as a first-generation medical device approved by the U.S. Food and Drug Administration (FDA) for the relief of the symptoms of skin pain, itch and inflammation associated with insect bites and stings. Therma Bright has been working on a TherOZap product that may provide a skin barrier to combat the Zika virus and other mosquito-borne diseases such as dengue, and it recently announced that final prototypes were sent to a research laboratory where testing of the technology against the Zika virus is underway (http://cnw.fm/N5ppQ).

Zika gained worldwide attention after an outbreak in 2015, and its apparent connection to Latin American children’s birth defects, such as the brain-damaging microcephaly head ailment, led the World Health Organization to declare the sexually transmitted virus a “Public Health Emergency of International Concern” because of its high potential for transnational transmission to other parts of the world (http://cnw.fm/Ape5R).

Dengue has been making news for decades as a viral infectious disease originating, like Zika, from mosquito bites. It used to be called “break-bone fever” because it sometimes causes severe joint and muscle pain that feels like bones are breaking. WHO estimates that there may be 50-100 million dengue cases around the world every year, although some analysts believe the number is higher (http://cnw.fm/h4gQ0).

Researchers have been reporting progress lately toward potential vaccines. Clinical trials are underway for Zika solutions (http://cnw.fm/2lBmC), and a partial dengue vaccine became commercially available in 11 countries in 2016 amid ongoing concerns about adverse responses in some vaccinated populations (http://cnw.fm/nVd0V).

Therma Bright’s novel barrier solution could provide a welcome response to medical concerns on a worldwide scale. The Zika trials are expected to last several months, an indication of their importance.

In October, Therma Bright revealed that it is also developing testing for a hemp cannabidiol (CBD)-based pain relief therapy that will use creams, gels or salves in concert with its thermal-generation products to target various forms of general or chronic pain such as back pain, arthritic pain and other orthopedic concerns. The company announced its first prototype in December.

Therma Bright’s attention to such a variety of skin care concerns positions it well within the cosmeceuticals market, which is expected to grow at a CAGR of 8.21 percent between 2017 and 2023, resulting in a worldwide market valued at $72.99 billion overall (http://cnw.fm/KC06a).

For more information, visit the company’s website at www.ThermaBright.com

* Based on double blind placebo study the InterceptCS™ is approved for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” by Health Canada. The InterceptCS™ is not approved by the United States FDA for any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

CannabisNewsWire is at the epicenter of the Cannabis Revolution.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Contact us: 303.498.7722